Roundup, deals, Life Sciences Bruce V. Bigelow wrote: It’s hard for any company to raise capital in this recession, but several San Diego life sciences startups disclosed last week they had done just that. A few bright spots also appeared during a local seminar on mergers and acquisitionsR...

Biotech, cancer, Drugs Luke Timmerman wrote: Off the coast of the Bahamas, in sea grass more than a half-mile deep, San Diego-based Nereus Pharmaceuticals found a fungus that may be the key ingredient for an innovative new cancer drug. This will be a key year for gathering evidence that will either ...

Biotech, Hepatitis C, Life Sciences Luke Timmerman wrote: An early peek at data from Anadys Pharmaceuticals (NASDAQ: ANDS) suggests the company may have a promising new drug in the works for hepatitis C. The San Diego-based biotech is announcing results today from the first eight patients with the c...

Biotech, Cash, Life Sciences Luke Timmerman wrote: Boston is the biggest center of life sciences in the Xconomy network, and by our analysis, the Bay State’s biotech sector is also the best equipped to survive the economic crisis. I reached this conclusion by combing through public company fil...